Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase
暂无分享,去创建一个
Masahiro Fukuoka | Kenji Tamura | Junji Uchida | Taroh Satoh | Kazuhiko Nakagawa | Tsutomu Iwasa | M. Fukuoka | K. Tamura | T. Satoh | J. Uchida | I. Okamoto | K. Nakagawa | T. Okabe | Isamu Okamoto | E. Hatashita | Takeshi Yoshida | Takafumi Okabe | Erina Hatashita | Yuki Yamada | Sayaka Tsukioka | T. Iwasa | Takeshi Yoshida | S. Tsukioka | Y. Yamada | Tsutomu Iwasa
[1] G. Bepler,et al. Activated Epidermal Growth Factor Receptor–Stat-3 Signaling Promotes Tumor Survival In vivo in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[2] F. Khuri,et al. Tumor Growth Inhibition by Simultaneously Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 in a Xenograft Model , 2005, Clinical Cancer Research.
[3] J. Schlessinger,et al. Signaling by Receptor Tyrosine Kinases , 1993 .
[4] Ju-Hee Lee,et al. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells , 2006, Molecular Cancer Therapeutics.
[5] Renato Martins,et al. Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.
[6] J. Schlessinger,et al. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[7] S. Varambally,et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). , 2005, Cancer research.
[8] J. Nevins,et al. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes , 1995, Molecular and cellular biology.
[9] Yusuke Nakajima,et al. Co‐regulation of B‐Myb expression by E2F1 and EGF receptor , 2006, Molecular carcinogenesis.
[10] M. Ratain,et al. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. , 1997, Journal of the National Cancer Institute.
[11] S. Groshen,et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] N. Saijo,et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CPT‐11 (irinotecan) in human colorectal cancer cells , 2004, International journal of cancer.
[13] C. Allegra,et al. Interaction of γ Interferon and 5-Fluorouracil in the H630 Human Colon Carcinoma Cell Line , 1990 .
[14] R. Gelber,et al. Prognostic importance of thymidylate synthase expression in early breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] C. Heidelberger,et al. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. , 1982, Cancer research.
[16] M. Kawahara,et al. [Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer]. , 2006, Gan to kagaku ryoho. Cancer & chemotherapy.
[17] M. Fukushima,et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. , 1996, Anti-cancer drugs.
[18] S. Toyooka,et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] A. Gazdar,et al. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers , 2006, International journal of cancer.
[20] P. Johnston,et al. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. , 1992, Cancer research.
[21] Kazuhiro Yoshida,et al. Synergistic effects of docetaxel and S‐1 by modulating the expression of metabolic enzymes of 5‐fluorouracil in human gastric cancer cell lines , 2006, International journal of cancer.
[22] Young Tae Kim,et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Siobhan McCormack,et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors , 2006, Molecular Cancer Therapeutics.
[24] C. Tei,et al. Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity. , 2006, Anticancer research.
[25] P. Johnston,et al. Thymidylate synthase and drug resistance. , 1995, European journal of cancer.
[26] M. Fukushima,et al. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. , 1993, Cancer research.
[27] W. Park,et al. Absence of EGFR mutation in the kinase domain in common human cancers besides non‐small cell lung cancer , 2005, International journal of cancer.
[28] N. Dyson. The regulation of E2F by pRB-family proteins. , 1998, Genes & development.
[29] S. Groshen,et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] T. Shibata,et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] L. Loeb,et al. Distribution of Mutations in Human Thymidylate Synthase Yielding Resistance to 5-Fluorodeoxyuridine* , 2002, Journal of Biological Chemistry.
[32] L. Bernstein,et al. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. , 1988, Cancer research.
[33] Y. Ichinose,et al. S-1 Plus Cisplatin Combination Chemotherapy in Patients with Advanced Non–Small Cell Lung Cancer , 2004, Clinical Cancer Research.
[34] Jon Brumbaugh,et al. DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION , 2000 .
[35] John Mendelsohn,et al. The EGF receptor family as targets for cancer therapy , 2000, Oncogene.
[36] Chan Zeng,et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[38] M. Fukuoka,et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] E. Van Cutsem,et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] H. Lane,et al. ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.
[41] M. Fukushima,et al. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. , 1987, Japanese journal of cancer research : Gann.
[42] P. Johnston,et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.
[43] S. Kane,et al. Desensitization and sensitization of cells to fluoropyrimidines with different antisenses directed against thymidylate synthase messenger RNA. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] W. Ichikawa,et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[45] P. Johnston,et al. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non–small cell lung cancer cells , 2006, Molecular Cancer Therapeutics.
[46] M C Berenbaum,et al. Criteria for analyzing interactions between biologically active agents. , 1981, Advances in cancer research.
[47] C. Allegra,et al. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. , 1995, Biochemical pharmacology.
[48] J. Lehár,et al. Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[49] J. Kendrew,et al. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor , 2005, Molecular Cancer Therapeutics.
[50] W. Washtien. Increased levels of thymidylate synthetase in cells exposed to 5-fluorouracil. , 1984, Molecular pharmacology.
[51] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[52] Oprs Alert. Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers , 2005 .
[53] J. Rigas,et al. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] M. Fukuoka,et al. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. , 2007, Cancer research.
[56] B. Murphy,et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] G. Schwartz,et al. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[58] Lesley Seymour,et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.
[59] Sandra Van Schaeybroeck,et al. Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy , 2005, Clinical Cancer Research.
[60] J. Baselga,et al. Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225) , 2004, Clinical Cancer Research.
[61] N. Dean,et al. Antisense down‐regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5‐FUdR, 5‐FU and Tomudex in HeLa cells , 1999, British journal of pharmacology.
[62] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[63] Takayuki Kosaka,et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] Jeffrey M. Trimarchi,et al. Transcription: Sibling rivalry in the E2F family , 2002, Nature Reviews Molecular Cell Biology.
[65] Hiroyuki Sakurai,et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas , 2005, Cancer.
[66] K. Kinzler,et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. , 2004, The New England journal of medicine.
[67] D. Ginsberg. EGFR Signaling Inhibits E2F1-Induced Apoptosis in Vivo: Implications for Cancer Therapy , 2007, Science's STKE.
[68] J. Schlessinger. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[69] K. Gibson,et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. , 2002, Cancer research.
[70] J. Cooper,et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. , 1992, The New England journal of medicine.
[71] Kevin Carroll,et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.
[72] S. Steinberg,et al. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] F Vignon,et al. [Growth factors and cancer]. , 1994, Journal de gynecologie, obstetrique et biologie de la reproduction.